{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:56:54Z","timestamp":1760317014310,"version":"build-2065373602"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T00:00:00Z","timestamp":1287446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Higher\u2010risk myelodysplastic syndromes (MDS) are similar pathobiologically to acute myeloid leukemia (AML), particularly in older adults. AML therapies thus may have activity in MDS. In the current study, phase 2 study data of arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in CD33\u2010positive patients with MDS and secondary AML (sAML) were presented.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Between June 2004 and February 2006, 30 patients with higher\u2010risk MDS or sAML received ATO (at a dose of 0.25 mg\/kg intravenously for 5 days during Week 1, then twice weekly during Weeks 2\u201012) and GO (at a dose of 3 mg\/m<jats:sup>2<\/jats:sup> on Day 8) for 1 or 2 cycles of 12 weeks each. The primary endpoint was response as per MDS or AML International Working Group (IWG) criteria. Adverse events were collected throughout treatment. Patients were followed for a minimum of 3 years for survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>The median patient age was 69 years. A total of 18 patients had MDS, 12 had sAML, and 19 had been previously treated. Seventeen patients (57%) completed \u22651 cycle, and 7 patients (23%) completed 2 cycles. IWG responses occurred in 9 patients (30%) according to IWG MDS criteria (including 2 of 7 patients who failed hypomethylating agents) and 3 of 12 AML patients (25%) according to IWG AML criteria. Grade 3\/4 (according to National Cancer Institute Common Toxicity Criteria [version 3.0]) thrombocytopenia occurred in 47% of patients, neutropenia in 63%, and anemia in 37% of patients. The median overall survival was 9.7 months (28.6 months in responders and 7.6 months in nonresponders; <jats:italic>P<\/jats:italic> &lt;.001). Patients who completed 2 cycles of therapy spent a median of 13 days in the hospital.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Combination therapy with ATO and GO was found to have acceptable response rates and toxicity, and may be a viable treatment option to standard induction therapy, particularly for patients who fail therapy with hypomethylating agents. Cancer 2011. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.25686","type":"journal-article","created":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T10:57:36Z","timestamp":1287485856000},"page":"1253-1261","source":"Crossref","is-referenced-by-count":29,"title":["A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia"],"prefix":"10.1002","volume":"117","author":[{"given":"Mikkael A.","family":"Sekeres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry P.","family":"Erba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Afable","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricki","family":"Englehaupt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Sobecks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Advani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry","family":"Seel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt E.","family":"Kalaycio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,10,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22570"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb02771.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn349"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.11.3022.3022"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008375931236"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb04063.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850801)56:3<553::AID-CNCR2820560323>3.0.CO;2-Q"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1987.tb00008.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1987.tb06138.x"},{"issue":"4","key":"e_1_2_6_13_2","first-page":"2","article-title":"Antibody\u2010targeted therapy for myeloid leukemia","volume":"36","author":"Appelbaum FR.","year":"1999","journal-title":"Semin Hematol."},{"key":"e_1_2_6_14_2","first-page":"3323","article-title":"Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy","volume":"89","author":"Leith CP","year":"1997","journal-title":"A Southwest Oncology Group study. Blood."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401711"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-082404"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3244"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody\u2010targeted chemotherapy: a phase I study of an anti\u2010CD33 calicheamicin immunoconjugate","volume":"93","author":"Sievers EL","year":"1999","journal-title":"Blood."},{"key":"e_1_2_6_20_2","first-page":"3345","volume":"89","author":"Chen GQ","year":"1997","journal-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose\u2010dependent dual effects on APL cells."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.3.1052.1052"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1525"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.9503"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.7903"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1199"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0772"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_6_29_2","doi-asserted-by":"crossref","unstructured":"FaderlS Garcia\u2010ManeroG RavandiF et al. Oral (po) and intravenous (iv) clofarabine for patients (pts) with myelodysplastic syndrome (MDS). ASH Annual Meeting Abstracts. 2008;112:222\u2010. Available at:http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/ashmtg;112\/11\/222.","DOI":"10.1182\/blood.V112.11.222.222"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22496"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25686","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:25:27Z","timestamp":1760300727000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,19]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,3,15]]}},"alternative-id":["10.1002\/cncr.25686"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25686","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2010,10,19]]}}}